nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Prednisolone—multiple sclerosis	0.13	0.185	CbGbCtD
Nevirapine—CYP2D6—Fingolimod—multiple sclerosis	0.099	0.141	CbGbCtD
Nevirapine—CYP2A6—Dexamethasone—multiple sclerosis	0.0767	0.109	CbGbCtD
Nevirapine—CYP3A4—Fingolimod—multiple sclerosis	0.0629	0.0897	CbGbCtD
Nevirapine—CYP2B6—Dexamethasone—multiple sclerosis	0.0499	0.0712	CbGbCtD
Nevirapine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0405	0.0578	CbGbCtD
Nevirapine—CYP3A5—Dexamethasone—multiple sclerosis	0.0393	0.0561	CbGbCtD
Nevirapine—CYP3A4—Triamcinolone—multiple sclerosis	0.0307	0.0438	CbGbCtD
Nevirapine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0296	0.0422	CbGbCtD
Nevirapine—CYP2C9—Dexamethasone—multiple sclerosis	0.0264	0.0376	CbGbCtD
Nevirapine—CYP3A4—Betamethasone—multiple sclerosis	0.0264	0.0376	CbGbCtD
Nevirapine—CYP3A4—Prednisolone—multiple sclerosis	0.026	0.0371	CbGbCtD
Nevirapine—CYP3A4—Prednisone—multiple sclerosis	0.0246	0.035	CbGbCtD
Nevirapine—CYP2D6—Dexamethasone—multiple sclerosis	0.0241	0.0344	CbGbCtD
Nevirapine—CYP3A4—Dexamethasone—multiple sclerosis	0.0153	0.0219	CbGbCtD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000568	0.0251	CbGpPWpGaD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000568	0.0251	CbGpPWpGaD
Nevirapine—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000547	0.0241	CbGpPWpGaD
Nevirapine—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.000492	0.0217	CbGpPWpGaD
Nevirapine—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000448	0.00163	CcSEcCtD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000447	0.0197	CbGpPWpGaD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000447	0.0197	CbGpPWpGaD
Nevirapine—Erythema—Prednisolone—multiple sclerosis	0.000445	0.00161	CcSEcCtD
Nevirapine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000443	0.00161	CcSEcCtD
Nevirapine—Oedema—Mitoxantrone—multiple sclerosis	0.000443	0.00161	CcSEcCtD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000441	0.0195	CbGpPWpGaD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000441	0.0195	CbGpPWpGaD
Nevirapine—Neutropenia—Prednisone—multiple sclerosis	0.000434	0.00157	CcSEcCtD
Nevirapine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000434	0.00157	CcSEcCtD
Nevirapine—Body temperature increased—Azathioprine—multiple sclerosis	0.000433	0.00157	CcSEcCtD
Nevirapine—Abdominal pain—Azathioprine—multiple sclerosis	0.000433	0.00157	CcSEcCtD
Nevirapine—Skin disorder—Mitoxantrone—multiple sclerosis	0.00043	0.00156	CcSEcCtD
Nevirapine—Vomiting—Cladribine—multiple sclerosis	0.000429	0.00155	CcSEcCtD
Nevirapine—Rash—Cladribine—multiple sclerosis	0.000425	0.00154	CcSEcCtD
Nevirapine—Dermatitis—Cladribine—multiple sclerosis	0.000425	0.00154	CcSEcCtD
Nevirapine—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000424	0.00154	CcSEcCtD
Nevirapine—Anorexia—Mitoxantrone—multiple sclerosis	0.000422	0.00153	CcSEcCtD
Nevirapine—Headache—Cladribine—multiple sclerosis	0.000422	0.00153	CcSEcCtD
Nevirapine—Hyperglycaemia—Prednisone—multiple sclerosis	0.000419	0.00152	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000415	0.0015	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000413	0.0015	CcSEcCtD
Nevirapine—Erythema—Triamcinolone—multiple sclerosis	0.00041	0.00149	CcSEcCtD
Nevirapine—Erythema—Methylprednisolone—multiple sclerosis	0.000409	0.00148	CcSEcCtD
Nevirapine—Angioedema—Prednisolone—multiple sclerosis	0.000407	0.00148	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000406	0.00147	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000404	0.00147	CcSEcCtD
Nevirapine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000404	0.00146	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000404	0.00146	CcSEcCtD
Nevirapine—Malaise—Prednisolone—multiple sclerosis	0.000402	0.00146	CcSEcCtD
Nevirapine—Nausea—Cladribine—multiple sclerosis	0.0004	0.00145	CcSEcCtD
Nevirapine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000398	0.00144	CcSEcCtD
Nevirapine—Somnolence—Mitoxantrone—multiple sclerosis	0.000394	0.00143	CcSEcCtD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000392	0.0173	CbGpPWpGaD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000392	0.0173	CbGpPWpGaD
Nevirapine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000385	0.0014	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—multiple sclerosis	0.000384	0.00139	CcSEcCtD
Nevirapine—Fatigue—Mitoxantrone—multiple sclerosis	0.000382	0.00139	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—multiple sclerosis	0.000381	0.00138	CcSEcCtD
Nevirapine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00038	0.00138	CcSEcCtD
Nevirapine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000379	0.00137	CcSEcCtD
Nevirapine—Pain—Mitoxantrone—multiple sclerosis	0.000379	0.00137	CcSEcCtD
Nevirapine—Diarrhoea—Azathioprine—multiple sclerosis	0.000375	0.00136	CcSEcCtD
Nevirapine—Discomfort—Prednisolone—multiple sclerosis	0.000375	0.00136	CcSEcCtD
Nevirapine—Angioedema—Triamcinolone—multiple sclerosis	0.000374	0.00136	CcSEcCtD
Nevirapine—Angioedema—Methylprednisolone—multiple sclerosis	0.000373	0.00135	CcSEcCtD
Nevirapine—Erythema—Betamethasone—multiple sclerosis	0.000372	0.00135	CcSEcCtD
Nevirapine—Erythema—Dexamethasone—multiple sclerosis	0.000372	0.00135	CcSEcCtD
Nevirapine—Malaise—Triamcinolone—multiple sclerosis	0.000369	0.00134	CcSEcCtD
Nevirapine—Malaise—Methylprednisolone—multiple sclerosis	0.000369	0.00134	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—multiple sclerosis	0.000365	0.00132	CcSEcCtD
Nevirapine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000365	0.00132	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000363	0.00132	CcSEcCtD
Nevirapine—Oedema—Prednisolone—multiple sclerosis	0.000363	0.00132	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—multiple sclerosis	0.000363	0.00132	CcSEcCtD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000363	0.016	CbGpPWpGaD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000363	0.016	CbGpPWpGaD
Nevirapine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000362	0.00131	CcSEcCtD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000361	0.0159	CbGpPWpGaD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000361	0.0159	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000356	0.0157	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000356	0.0157	CbGpPWpGaD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000353	0.0156	CbGpPWpGaD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000353	0.0156	CbGpPWpGaD
Nevirapine—Urticaria—Mitoxantrone—multiple sclerosis	0.000352	0.00128	CcSEcCtD
Nevirapine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00035	0.00127	CcSEcCtD
Nevirapine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00035	0.00127	CcSEcCtD
Nevirapine—Myalgia—Triamcinolone—multiple sclerosis	0.000349	0.00126	CcSEcCtD
Nevirapine—Vomiting—Azathioprine—multiple sclerosis	0.000348	0.00126	CcSEcCtD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000348	0.0154	CbGpPWpGaD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000348	0.0154	CbGpPWpGaD
Nevirapine—Myalgia—Methylprednisolone—multiple sclerosis	0.000348	0.00126	CcSEcCtD
Nevirapine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000348	0.00126	CcSEcCtD
Nevirapine—Rash—Azathioprine—multiple sclerosis	0.000346	0.00125	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000346	0.00125	CcSEcCtD
Nevirapine—Dermatitis—Azathioprine—multiple sclerosis	0.000345	0.00125	CcSEcCtD
Nevirapine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000345	0.00125	CcSEcCtD
Nevirapine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000345	0.00125	CcSEcCtD
Nevirapine—Discomfort—Triamcinolone—multiple sclerosis	0.000345	0.00125	CcSEcCtD
Nevirapine—Discomfort—Methylprednisolone—multiple sclerosis	0.000344	0.00125	CcSEcCtD
Nevirapine—Headache—Azathioprine—multiple sclerosis	0.000343	0.00125	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000343	0.00124	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—multiple sclerosis	0.00034	0.00123	CcSEcCtD
Nevirapine—Angioedema—Dexamethasone—multiple sclerosis	0.00034	0.00123	CcSEcCtD
Nevirapine—Angioedema—Betamethasone—multiple sclerosis	0.00034	0.00123	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—multiple sclerosis	0.000336	0.00122	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—multiple sclerosis	0.000336	0.00122	CcSEcCtD
Nevirapine—Malaise—Betamethasone—multiple sclerosis	0.000335	0.00122	CcSEcCtD
Nevirapine—Malaise—Dexamethasone—multiple sclerosis	0.000335	0.00122	CcSEcCtD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000335	0.0148	CbGpPWpGaD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000335	0.0148	CbGpPWpGaD
Nevirapine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000334	0.00121	CcSEcCtD
Nevirapine—Oedema—Triamcinolone—multiple sclerosis	0.000334	0.00121	CcSEcCtD
Nevirapine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000334	0.00121	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000327	0.00119	CcSEcCtD
Nevirapine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000327	0.00119	CcSEcCtD
Nevirapine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000326	0.00118	CcSEcCtD
Nevirapine—Paraesthesia—Prednisolone—multiple sclerosis	0.000326	0.00118	CcSEcCtD
Nevirapine—Nausea—Azathioprine—multiple sclerosis	0.000326	0.00118	CcSEcCtD
Nevirapine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000324	0.00117	CcSEcCtD
Nevirapine—Erythema—Prednisone—multiple sclerosis	0.000324	0.00117	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000323	0.00117	CcSEcCtD
Nevirapine—Asthenia—Mitoxantrone—multiple sclerosis	0.000318	0.00115	CcSEcCtD
Nevirapine—Myalgia—Betamethasone—multiple sclerosis	0.000316	0.00115	CcSEcCtD
Nevirapine—Myalgia—Dexamethasone—multiple sclerosis	0.000316	0.00115	CcSEcCtD
Nevirapine—Discomfort—Betamethasone—multiple sclerosis	0.000313	0.00113	CcSEcCtD
Nevirapine—Discomfort—Dexamethasone—multiple sclerosis	0.000313	0.00113	CcSEcCtD
Nevirapine—Pain—Prednisolone—multiple sclerosis	0.000311	0.00113	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—multiple sclerosis	0.000311	0.00113	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000305	0.0011	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000304	0.0011	CcSEcCtD
Nevirapine—Oedema—Betamethasone—multiple sclerosis	0.000303	0.0011	CcSEcCtD
Nevirapine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000303	0.0011	CcSEcCtD
Nevirapine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000303	0.0011	CcSEcCtD
Nevirapine—Oedema—Dexamethasone—multiple sclerosis	0.000303	0.0011	CcSEcCtD
Nevirapine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000303	0.0011	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—multiple sclerosis	0.0003	0.00109	CcSEcCtD
Nevirapine—Paraesthesia—Triamcinolone—multiple sclerosis	0.0003	0.00109	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisolone—multiple sclerosis	0.0003	0.00109	CcSEcCtD
Nevirapine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000299	0.00109	CcSEcCtD
Nevirapine—Anaemia—Prednisone—multiple sclerosis	0.000299	0.00108	CcSEcCtD
Nevirapine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000297	0.00108	CcSEcCtD
Nevirapine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000297	0.00108	CcSEcCtD
Nevirapine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000297	0.00108	CcSEcCtD
Nevirapine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000297	0.00108	CcSEcCtD
Nevirapine—Angioedema—Prednisone—multiple sclerosis	0.000296	0.00107	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000294	0.00107	CcSEcCtD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000293	0.0129	CbGpPWpGaD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000293	0.0129	CbGpPWpGaD
Nevirapine—Malaise—Prednisone—multiple sclerosis	0.000292	0.00106	CcSEcCtD
Nevirapine—Anorexia—Betamethasone—multiple sclerosis	0.000289	0.00105	CcSEcCtD
Nevirapine—Anorexia—Dexamethasone—multiple sclerosis	0.000289	0.00105	CcSEcCtD
Nevirapine—Urticaria—Prednisolone—multiple sclerosis	0.000289	0.00105	CcSEcCtD
Nevirapine—Fatigue—Triamcinolone—multiple sclerosis	0.000288	0.00105	CcSEcCtD
Nevirapine—Fatigue—Methylprednisolone—multiple sclerosis	0.000288	0.00104	CcSEcCtD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000286	0.0126	CbGpPWpGaD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000286	0.0126	CbGpPWpGaD
Nevirapine—Pain—Triamcinolone—multiple sclerosis	0.000286	0.00104	CcSEcCtD
Nevirapine—Vomiting—Mitoxantrone—multiple sclerosis	0.000282	0.00102	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—multiple sclerosis	0.000281	0.00102	CcSEcCtD
Nevirapine—Rash—Mitoxantrone—multiple sclerosis	0.000279	0.00101	CcSEcCtD
Nevirapine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000279	0.00101	CcSEcCtD
Nevirapine—Headache—Mitoxantrone—multiple sclerosis	0.000278	0.00101	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000276	0.001	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000276	0.001	CcSEcCtD
Nevirapine—Myalgia—Prednisone—multiple sclerosis	0.000276	0.000999	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—multiple sclerosis	0.000276	0.000999	CcSEcCtD
Nevirapine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000275	0.000999	CcSEcCtD
Nevirapine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000275	0.000997	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000274	0.000992	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000273	0.000989	CcSEcCtD
Nevirapine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000272	0.000988	CcSEcCtD
Nevirapine—Paraesthesia—Betamethasone—multiple sclerosis	0.000272	0.000988	CcSEcCtD
Nevirapine—Discomfort—Prednisone—multiple sclerosis	0.000272	0.000987	CcSEcCtD
Nevirapine—Erythema—Methotrexate—multiple sclerosis	0.00027	0.000981	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000268	0.000971	CcSEcCtD
Nevirapine—Urticaria—Triamcinolone—multiple sclerosis	0.000266	0.000963	CcSEcCtD
Nevirapine—Urticaria—Methylprednisolone—multiple sclerosis	0.000265	0.000961	CcSEcCtD
Nevirapine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000264	0.000958	CcSEcCtD
Nevirapine—Oedema—Prednisone—multiple sclerosis	0.000264	0.000958	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000264	0.000958	CcSEcCtD
Nevirapine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000264	0.000956	CcSEcCtD
Nevirapine—Decreased appetite—Betamethasone—multiple sclerosis	0.000264	0.000956	CcSEcCtD
Nevirapine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000264	0.000956	CcSEcCtD
Nevirapine—Nausea—Mitoxantrone—multiple sclerosis	0.000263	0.000954	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000262	0.000949	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000262	0.000949	CcSEcCtD
Nevirapine—Fatigue—Betamethasone—multiple sclerosis	0.000261	0.000948	CcSEcCtD
Nevirapine—Fatigue—Dexamethasone—multiple sclerosis	0.000261	0.000948	CcSEcCtD
Nevirapine—Pain—Betamethasone—multiple sclerosis	0.000259	0.00094	CcSEcCtD
Nevirapine—Pain—Dexamethasone—multiple sclerosis	0.000259	0.00094	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—multiple sclerosis	0.000259	0.000939	CcSEcCtD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000258	0.0114	CbGpPWpGaD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000258	0.0114	CbGpPWpGaD
Nevirapine—Skin disorder—Prednisone—multiple sclerosis	0.000257	0.00093	CcSEcCtD
Nevirapine—Anorexia—Prednisone—multiple sclerosis	0.000252	0.000913	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000251	0.00091	CcSEcCtD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000251	0.0111	CbGpPWpGaD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000251	0.0111	CbGpPWpGaD
Nevirapine—Anaemia—Methotrexate—multiple sclerosis	0.00025	0.000907	CcSEcCtD
Nevirapine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00025	0.000906	CcSEcCtD
Nevirapine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00025	0.000906	CcSEcCtD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000249	0.011	CbGpPWpGaD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000249	0.011	CbGpPWpGaD
Nevirapine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000248	0.000899	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000248	0.000899	CcSEcCtD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000248	0.0109	CbGpPWpGaD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000248	0.0109	CbGpPWpGaD
Nevirapine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000246	0.000893	CcSEcCtD
Nevirapine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000246	0.000891	CcSEcCtD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000245	0.0108	CbGpPWpGaD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000245	0.0108	CbGpPWpGaD
Nevirapine—Malaise—Methotrexate—multiple sclerosis	0.000244	0.000884	CcSEcCtD
Nevirapine—Urticaria—Betamethasone—multiple sclerosis	0.000241	0.000874	CcSEcCtD
Nevirapine—Urticaria—Dexamethasone—multiple sclerosis	0.000241	0.000874	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000241	0.000873	CcSEcCtD
Nevirapine—Asthenia—Triamcinolone—multiple sclerosis	0.00024	0.00087	CcSEcCtD
Nevirapine—Body temperature increased—Betamethasone—multiple sclerosis	0.00024	0.000869	CcSEcCtD
Nevirapine—Body temperature increased—Dexamethasone—multiple sclerosis	0.00024	0.000869	CcSEcCtD
Nevirapine—Abdominal pain—Dexamethasone—multiple sclerosis	0.00024	0.000869	CcSEcCtD
Nevirapine—Abdominal pain—Betamethasone—multiple sclerosis	0.00024	0.000869	CcSEcCtD
Nevirapine—Asthenia—Methylprednisolone—multiple sclerosis	0.000239	0.000868	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—multiple sclerosis	0.000237	0.00086	CcSEcCtD
Nevirapine—Pruritus—Triamcinolone—multiple sclerosis	0.000236	0.000858	CcSEcCtD
Nevirapine—Pruritus—Methylprednisolone—multiple sclerosis	0.000236	0.000856	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—multiple sclerosis	0.00023	0.000835	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—multiple sclerosis	0.00023	0.000835	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—multiple sclerosis	0.00023	0.000833	CcSEcCtD
Nevirapine—Rash—Prednisolone—multiple sclerosis	0.000229	0.000831	CcSEcCtD
Nevirapine—Dermatitis—Prednisolone—multiple sclerosis	0.000229	0.00083	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000229	0.000829	CcSEcCtD
Nevirapine—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000229	0.0101	CbGpPWpGaD
Nevirapine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000228	0.000827	CcSEcCtD
Nevirapine—Fatigue—Prednisone—multiple sclerosis	0.000228	0.000826	CcSEcCtD
Nevirapine—Headache—Prednisolone—multiple sclerosis	0.000228	0.000826	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—multiple sclerosis	0.000228	0.000825	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000221	0.0008	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—multiple sclerosis	0.000218	0.000789	CcSEcCtD
Nevirapine—Asthenia—Betamethasone—multiple sclerosis	0.000218	0.000789	CcSEcCtD
Nevirapine—Asthenia—Dexamethasone—multiple sclerosis	0.000218	0.000789	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000216	0.000785	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000216	0.000784	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000216	0.000783	CcSEcCtD
Nevirapine—Nausea—Prednisolone—multiple sclerosis	0.000216	0.000783	CcSEcCtD
Nevirapine—Pruritus—Betamethasone—multiple sclerosis	0.000215	0.000778	CcSEcCtD
Nevirapine—Pruritus—Dexamethasone—multiple sclerosis	0.000215	0.000778	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—multiple sclerosis	0.000214	0.000777	CcSEcCtD
Nevirapine—Vomiting—Triamcinolone—multiple sclerosis	0.000213	0.000771	CcSEcCtD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000212	0.00937	CbGpPWpGaD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000212	0.00937	CbGpPWpGaD
Nevirapine—Vomiting—Methylprednisolone—multiple sclerosis	0.000212	0.000769	CcSEcCtD
Nevirapine—Rash—Triamcinolone—multiple sclerosis	0.000211	0.000764	CcSEcCtD
Nevirapine—Dermatitis—Triamcinolone—multiple sclerosis	0.000211	0.000764	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—multiple sclerosis	0.00021	0.000763	CcSEcCtD
Nevirapine—Rash—Methylprednisolone—multiple sclerosis	0.00021	0.000763	CcSEcCtD
Nevirapine—Dermatitis—Methylprednisolone—multiple sclerosis	0.00021	0.000762	CcSEcCtD
Nevirapine—Urticaria—Prednisone—multiple sclerosis	0.00021	0.000761	CcSEcCtD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00021	0.00925	CbGpPWpGaD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00021	0.00925	CbGpPWpGaD
Nevirapine—Headache—Triamcinolone—multiple sclerosis	0.000209	0.000759	CcSEcCtD
Nevirapine—Headache—Methylprednisolone—multiple sclerosis	0.000209	0.000758	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—multiple sclerosis	0.000209	0.000757	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—multiple sclerosis	0.000209	0.000757	CcSEcCtD
Nevirapine—Diarrhoea—Betamethasone—multiple sclerosis	0.000208	0.000752	CcSEcCtD
Nevirapine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000208	0.000752	CcSEcCtD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000203	0.00897	CbGpPWpGaD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000203	0.00897	CbGpPWpGaD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000202	0.00889	CbGpPWpGaD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000202	0.00889	CbGpPWpGaD
Nevirapine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000201	0.000729	CcSEcCtD
Nevirapine—Nausea—Triamcinolone—multiple sclerosis	0.000199	0.00072	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—multiple sclerosis	0.000198	0.000719	CcSEcCtD
Nevirapine—Nausea—Methylprednisolone—multiple sclerosis	0.000198	0.000718	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—multiple sclerosis	0.000196	0.000712	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—multiple sclerosis	0.000195	0.000706	CcSEcCtD
Nevirapine—Vomiting—Dexamethasone—multiple sclerosis	0.000193	0.000699	CcSEcCtD
Nevirapine—Vomiting—Betamethasone—multiple sclerosis	0.000193	0.000699	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000193	0.0085	CbGpPWpGaD
Nevirapine—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000193	0.0085	CbGpPWpGaD
Nevirapine—Decreased appetite—Methotrexate—multiple sclerosis	0.000192	0.000696	CcSEcCtD
Nevirapine—Rash—Betamethasone—multiple sclerosis	0.000191	0.000693	CcSEcCtD
Nevirapine—Rash—Dexamethasone—multiple sclerosis	0.000191	0.000693	CcSEcCtD
Nevirapine—Dermatitis—Dexamethasone—multiple sclerosis	0.000191	0.000693	CcSEcCtD
Nevirapine—Dermatitis—Betamethasone—multiple sclerosis	0.000191	0.000693	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000191	0.000691	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—multiple sclerosis	0.00019	0.00069	CcSEcCtD
Nevirapine—Headache—Betamethasone—multiple sclerosis	0.00019	0.000689	CcSEcCtD
Nevirapine—Headache—Dexamethasone—multiple sclerosis	0.00019	0.000689	CcSEcCtD
Nevirapine—Asthenia—Prednisone—multiple sclerosis	0.00019	0.000687	CcSEcCtD
Nevirapine—Pain—Methotrexate—multiple sclerosis	0.000189	0.000685	CcSEcCtD
Nevirapine—Pruritus—Prednisone—multiple sclerosis	0.000187	0.000678	CcSEcCtD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000186	0.0082	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000182	0.00804	CbGpPWpGaD
Nevirapine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000182	0.00066	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—multiple sclerosis	0.000181	0.000655	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000181	0.000655	CcSEcCtD
Nevirapine—Nausea—Dexamethasone—multiple sclerosis	0.00018	0.000653	CcSEcCtD
Nevirapine—Nausea—Betamethasone—multiple sclerosis	0.00018	0.000653	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—multiple sclerosis	0.000175	0.000636	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—multiple sclerosis	0.000174	0.000633	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—multiple sclerosis	0.000174	0.000633	CcSEcCtD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000172	0.0076	CbGpPWpGaD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000172	0.0076	CbGpPWpGaD
Nevirapine—Vomiting—Prednisone—multiple sclerosis	0.000168	0.000609	CcSEcCtD
Nevirapine—Rash—Prednisone—multiple sclerosis	0.000167	0.000604	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—multiple sclerosis	0.000166	0.000603	CcSEcCtD
Nevirapine—Headache—Prednisone—multiple sclerosis	0.000165	0.0006	CcSEcCtD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000164	0.00723	CbGpPWpGaD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000164	0.00723	CbGpPWpGaD
Nevirapine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000163	0.00059	CcSEcCtD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000162	0.00714	CbGpPWpGaD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000162	0.00714	CbGpPWpGaD
Nevirapine—Asthenia—Methotrexate—multiple sclerosis	0.000158	0.000574	CcSEcCtD
Nevirapine—Nausea—Prednisone—multiple sclerosis	0.000157	0.000569	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—multiple sclerosis	0.000156	0.000566	CcSEcCtD
Nevirapine—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	0.000155	0.00685	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	0.000155	0.00685	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000153	0.00676	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000153	0.00676	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000152	0.0067	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000152	0.0067	CbGpPWpGaD
Nevirapine—Diarrhoea—Methotrexate—multiple sclerosis	0.000151	0.000548	CcSEcCtD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00015	0.00661	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00015	0.00661	CbGpPWpGaD
Nevirapine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000147	0.00649	CbGpPWpGaD
Nevirapine—Vomiting—Methotrexate—multiple sclerosis	0.00014	0.000509	CcSEcCtD
Nevirapine—Rash—Methotrexate—multiple sclerosis	0.000139	0.000505	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—multiple sclerosis	0.000139	0.000504	CcSEcCtD
Nevirapine—Headache—Methotrexate—multiple sclerosis	0.000138	0.000501	CcSEcCtD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000133	0.00586	CbGpPWpGaD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000133	0.00586	CbGpPWpGaD
Nevirapine—Nausea—Methotrexate—multiple sclerosis	0.000131	0.000475	CcSEcCtD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000128	0.00565	CbGpPWpGaD
Nevirapine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000117	0.00518	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000114	0.00505	CbGpPWpGaD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000109	0.00483	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000108	0.00476	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000108	0.00476	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000107	0.00472	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000107	0.00472	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000107	0.0047	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000107	0.0047	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000106	0.00466	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000106	0.00466	CbGpPWpGaD
Nevirapine—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000101	0.00446	CbGpPWpGaD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000101	0.00444	CbGpPWpGaD
Nevirapine—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	9.95e-05	0.00439	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	9.15e-05	0.00404	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	9.15e-05	0.00404	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.02e-05	0.00398	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.02e-05	0.00398	CbGpPWpGaD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	8.45e-05	0.00373	CbGpPWpGaD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.16e-05	0.0036	CbGpPWpGaD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.12e-05	0.00358	CbGpPWpGaD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.93e-05	0.0035	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	7.06e-05	0.00311	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	7.06e-05	0.00311	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.96e-05	0.00307	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.96e-05	0.00307	CbGpPWpGaD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.58e-05	0.0029	CbGpPWpGaD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.43e-05	0.00284	CbGpPWpGaD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.64e-05	0.00249	CbGpPWpGaD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.59e-05	0.00247	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	4.92e-05	0.00217	CbGpPWpGaD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.78e-05	0.00211	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—SRM—multiple sclerosis	4.67e-05	0.00206	CbGpPWpGaD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.57e-05	0.00202	CbGpPWpGaD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.53e-05	0.002	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	4.39e-05	0.00194	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	4.37e-05	0.00193	CbGpPWpGaD
Nevirapine—CYP2A6—Biological oxidations—POMC—multiple sclerosis	4.33e-05	0.00191	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.11e-05	0.00181	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.11e-05	0.00181	CbGpPWpGaD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.87e-05	0.00171	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—SRM—multiple sclerosis	3.77e-05	0.00166	CbGpPWpGaD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.69e-05	0.00163	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—SRM—multiple sclerosis	3.69e-05	0.00163	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.51e-05	0.00155	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.51e-05	0.00155	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—POMC—multiple sclerosis	3.5e-05	0.00154	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	3.42e-05	0.00151	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.42e-05	0.00151	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	3.41e-05	0.0015	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.34e-05	0.00147	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	3.29e-05	0.00145	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	3.29e-05	0.00145	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.18e-05	0.0014	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.18e-05	0.0014	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GPC5—multiple sclerosis	3.01e-05	0.00133	CbGpPWpGaD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.99e-05	0.00132	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	2.85e-05	0.00126	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	2.66e-05	0.00117	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	2.66e-05	0.00117	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—SRM—multiple sclerosis	2.62e-05	0.00116	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—SRM—multiple sclerosis	2.6e-05	0.00115	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.6e-05	0.00115	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.6e-05	0.00115	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—RRM1—multiple sclerosis	2.5e-05	0.0011	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.43e-05	0.00107	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.43e-05	0.00107	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.41e-05	0.00106	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.38e-05	0.00105	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SRM—multiple sclerosis	2.22e-05	0.00098	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.06e-05	0.000908	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.01e-05	0.000888	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.97e-05	0.000868	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.85e-05	0.000815	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.85e-05	0.000815	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.83e-05	0.000808	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.83e-05	0.000808	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.79e-05	0.000789	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.71e-05	0.000756	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.69e-05	0.000745	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.67e-05	0.000739	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.59e-05	0.000701	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.56e-05	0.00069	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.56e-05	0.00069	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.53e-05	0.000675	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—BCHE—multiple sclerosis	1.43e-05	0.000632	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.43e-05	0.000631	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.4e-05	0.000617	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.39e-05	0.000612	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.21e-05	0.000533	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.21e-05	0.000533	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.19e-05	0.000523	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.16e-05	0.00051	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.13e-05	0.000499	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.1e-05	0.000487	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.08e-05	0.000475	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.25e-06	0.000408	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.2e-06	0.000406	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—RRM1—multiple sclerosis	9.15e-06	0.000404	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—APOE—multiple sclerosis	8.62e-06	0.00038	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.43e-06	0.000372	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—BCHE—multiple sclerosis	8.04e-06	0.000355	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—BCHE—multiple sclerosis	7.97e-06	0.000352	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.9e-06	0.000349	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—POMC—multiple sclerosis	7.41e-06	0.000327	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.21e-06	0.000318	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—APOE—multiple sclerosis	6.96e-06	0.000307	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—BCHE—multiple sclerosis	6.81e-06	0.0003	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—APOE—multiple sclerosis	6.8e-06	0.0003	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALB—multiple sclerosis	6.75e-06	0.000298	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—POMC—multiple sclerosis	5.98e-06	0.000264	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—POMC—multiple sclerosis	5.84e-06	0.000258	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALB—multiple sclerosis	5.45e-06	0.00024	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALB—multiple sclerosis	5.33e-06	0.000235	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.26e-06	0.000232	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—APOE—multiple sclerosis	4.84e-06	0.000213	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—APOE—multiple sclerosis	4.79e-06	0.000212	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—POMC—multiple sclerosis	4.15e-06	0.000183	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—POMC—multiple sclerosis	4.12e-06	0.000182	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—APOE—multiple sclerosis	4.1e-06	0.000181	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALB—multiple sclerosis	3.79e-06	0.000167	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALB—multiple sclerosis	3.76e-06	0.000166	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—POMC—multiple sclerosis	3.52e-06	0.000155	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALB—multiple sclerosis	3.21e-06	0.000142	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—APOE—multiple sclerosis	3.16e-06	0.000139	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—POMC—multiple sclerosis	2.72e-06	0.00012	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.48e-06	0.000109	CbGpPWpGaD
